Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy

Hum Vaccin Immunother. 2013 Jul;9(7):1545-8. doi: 10.4161/hv.24235. Epub 2013 Mar 8.

Abstract

Fusions of antigen presenting cells and tumor cells have been investigated in animal models and phase I/II clinical trials as candidate cancer vaccines. In animal studies there have been numerous reports of induction of protective immunity against a wide range of tumor types. Results of clinical trials have been less dramatic, but tumor-specific immune responses have been reported in many patients, with clinical responses to the vaccination in a subset. In this commentary article, I review the current status of antigen presenting cell/tumor cell fusion vaccines for cancer immunotherapy.

Keywords: antigen presenting cell; cancer; fusion; hybrid; tumour; vaccine.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigen-Presenting Cells / immunology*
  • CD4-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / immunology
  • Cancer Vaccines / immunology*
  • Cell Fusion
  • Cell- and Tissue-Based Therapy
  • Humans
  • Hybrid Cells / immunology*
  • Immunotherapy / methods*
  • Lymphocyte Activation
  • Mice
  • Neoplasms / immunology
  • Neoplasms / prevention & control*
  • Neoplasms / therapy*

Substances

  • Cancer Vaccines